clinprost profile

TTC 909: used to reduce ischaemic brain injury from post-ischaemic treatment [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

TEI 9090: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	6436040
CHEMBL ID	2104163
SCHEMBL ID	563750
MeSH ID	M0149865
PubMed CID	5282235
SCHEMBL ID	15645896
MeSH ID	M0149865

Synonym
lipo pgi2
ttc-909
clinprost
tei-9090
lipo-isocarbacyclin methyl ester
lipocurren
arteon
clinprost [inn]
2-pentalenepentanoic acid, 1,3a,4,5,6,6a-hexahydro-5-hydroxy-6-(3-hydroxy-1-octenyl)-, methyl ester, (3as-(3a-alpha,5-beta,6-alpha(1e,3r*),6a-alpha))-
ttc 909
(+)-methyl-(3as,5r,6r,6as)-1,3a,4,5,6,6a-hexahydro-5-hydroxy-6-((e)-(3s)-3-hydroxy-1-octenyl)-2-pentalenevalerate
isocarbacyclin methyl ester
88931-51-5
methyl 5-[(3as,5r,6r,6as)-5-hydroxy-6-[(e,3s)-3-hydroxyoct-1-enyl]-1,3a,4,5,6,6a-hexahydropentalen-2-yl]pentanoate
unii-6gri2j11n5
6gri2j11n5 ,
clinprost [jan]
2-pentalenepentanoic acid, 1,3a,4,5,6,6a-hexahydro-5-hydroxy-6-((1e,3s)-3-hydroxy-1-octen-1-yl)-, methyl ester, (3as,5r,6r,6as)-
clinprost [mi]
arteron
CHEMBL2104163
SCHEMBL563750
methyl 5-((3as,5r,6r,6as)-5-hydroxy-6-((s,e)-3-hydroxyoct-1-en-1-yl)-1,3a,4,5,6,6a-hexahydropentalen-2-yl)pentanoate
QIGRQPVOWVHYBT-KABTVRTISA-N
Q27264886
methyl (3as,5r,6r,6as)-1,3a,4,5,6,6a-hexahydro-5-hydroxy-6-[(1e,3s)-3-hydroxy-1-octen-1-yl]-2-pentalenepentanoate
DTXSID201107239
clinprost (jan/inn)
D02048
tei 9090
arteron (tn)
methyl 5-[(3as,5r,6r,6as)-5-hydroxy-6-[(e,3r)-3-hydroxyoct-1-enyl]-1,3a,4,5,6,6a-hexahydropentalen-2-yl]pentanoate
QIGRQPVOWVHYBT-IZNRJJTJSA-N
methyl 5-((3as,5r,6r,6as)-5-hydroxy-6-((r,e)-3-hydroxyoct-1-en-1-yl)-1,3a,4,5,6,6a-hexahydropentalen-2-yl)pentanoate
SCHEMBL15645896

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	2 (6.45)	18.7374
1990's	21 (67.74)	18.2507
2000's	5 (16.13)	29.6817
2010's	2 (6.45)	24.3611
2020's	1 (3.23)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	1 (6.25%)	5.53%
Trials	1 (6.25%)	5.53%
Reviews	0 (0.00%)	6.00%
Reviews	3 (18.75%)	6.00%
Case Studies	1 (6.25%)	4.05%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Observational	0 (0.00%)	0.25%
Other	14 (87.50%)	84.16%
Other	12 (75.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
3-aminobenzamide [no description available]	2.02	1	benzamides; substituted aniline	EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor
ethidium ethidium : The fluorescent compound widely used in experimental cell biology and biochemistry to reveal double-stranded DNA and RNA.. Ethidium: A trypanocidal agent and possible antiviral agent that is widely used in experimental cell biology and biochemistry. Ethidium has several experimentally useful properties including binding to nucleic acids, noncompetitive inhibition of nicotinic acetylcholine receptors, and fluorescence among others. It is most commonly used as the bromide.	2.01	1	phenanthridines	fluorochrome; intercalator
bromodeoxyuridine Bromodeoxyuridine: A nucleoside that substitutes for thymidine in DNA and thus acts as an antimetabolite. It causes breaks in chromosomes and has been proposed as an antiviral and antineoplastic agent. It has been given orphan drug status for use in the treatment of primary brain tumors.	2.01	1	pyrimidine 2'-deoxyribonucleoside	antimetabolite; antineoplastic agent
ergotamine Ergotamine: A vasoconstrictor found in ergot of Central Europe. It is a serotonin agonist that has been used as an oxytocic agent and in the treatment of MIGRAINE DISORDERS.. ergotamine : A peptide ergot alkaloid that is dihydroergotamine in which a double bond replaces the single bond between positions 9 and 10.	1.98	1	peptide ergot alkaloid	alpha-adrenergic agonist; mycotoxin; non-narcotic analgesic; oxytocic; serotonergic agonist; vasoconstrictor agent
acridine orange Acridine Orange: A cationic cytochemical stain specific for cell nuclei, especially DNA. It is used as a supravital stain and in fluorescence cytochemistry. It may cause mutations in microorganisms.. acridine orange : Fluorescent dye useful for cell cycle determination. It is cell-permeable, and interacts with DNA and RNA by intercalation or electrostatic attractions respectively.. acridine orange free base : A member of the class of aminoacridines that is acridine carrying two dimethylamino substituents at positions 3 and 6. The hydrochloride salt is the fluorescent dye 'acridine orange', used for cell cycle determination.	2.01	1	aminoacridines; aromatic amine; tertiary amino compound	fluorochrome; histological dye
stilbenes Stilbenes: Organic compounds that contain 1,2-diphenylethylene as a functional group.. trans-stilbene : The trans-isomer of stilbene.	2.02	1	stilbene
alprostadil [no description available]	2.39	2	prostaglandins E	anticoagulant; human metabolite; platelet aggregation inhibitor; vasodilator agent
trans-2,3',4,5'-tetrahydroxystilbene trans-2,3',4,5'-tetrahydroxystilbene: hydroxystilbene oxyresveratrol	2.02	1	stilbenoid
ozagrel ozagrel: RN refers to (E)-isomer	2.01	1	cinnamic acids
9-o-methanoprostaglandin i 9-O-methanoprostaglandin I: shows weak inhibitory activity in rabbit platelet aggregation induced by ADP; RN given refers to cpd without isomeric designation	1.98	1
cytochrome c-t Cytochromes c: Cytochromes of the c type that are found in eukaryotic MITOCHONDRIA. They serve as redox intermediates that accept electrons from MITOCHONDRIAL ELECTRON TRANSPORT COMPLEX III and transfer them to MITOCHONDRIAL ELECTRON TRANSPORT COMPLEX IV.	2.02	1
to-pro-1 To-Pro-1 : A C1 cyanine dye having benzothiazolium-2-yl and quinolinium-4-yl substituents.. TO-PRO-1: a nucleic acid binding probe	2.01	1	cyanine dye; organic iodide salt	fluorochrome
aspirin acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.. Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5). acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.	4.8	3	benzoic acids; phenyl acetates; salicylates	anticoagulant; antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; drug allergen; EC 1.1.1.188 (prostaglandin-F synthase) inhibitor; geroprotector; non-narcotic analgesic; non-steroidal anti-inflammatory drug; plant activator; platelet aggregation inhibitor; prostaglandin antagonist; teratogenic agent
erythrosine Fluoresceins: A family of spiro(isobenzofuran-1(3H),9'-(9H)xanthen)-3-one derivatives. These are used as dyes, as indicators for various metals, and as fluorescent labels in immunoassays.	1.97	1
1-methyl-3-isobutylxanthine 1-Methyl-3-isobutylxanthine: A potent cyclic nucleotide phosphodiesterase inhibitor; due to this action, the compound increases cyclic AMP and cyclic GMP in tissue and thereby activates CYCLIC NUCLEOTIDE-REGULATED PROTEIN KINASES. 3-isobutyl-1-methylxanthine : An oxopurine that is xanthine which is substituted at positions 1 and 3 by methyl and isobutyl groups, respectively.	1.97	1	3-isobutyl-1-methylxanthine
isoflurophate Isoflurophate: A di-isopropyl-fluorophosphate which is an irreversible cholinesterase inhibitor used to investigate the NERVOUS SYSTEM.	1.98	1	dialkyl phosphate
hydrazine diamine : Any polyamine that contains two amino groups.	1.98	1	azane; hydrazines	EC 4.3.1.10 (serine-sulfate ammonia-lyase) inhibitor
sodium dodecyl sulfate Sodium Dodecyl Sulfate: An anionic surfactant, usually a mixture of sodium alkyl sulfates, mainly the lauryl; lowers surface tension of aqueous solutions; used as fat emulsifier, wetting agent, detergent in cosmetics, pharmaceuticals and toothpastes; also as research tool in protein biochemistry.. sodium dodecyl sulfate : An organic sodium salt that is the sodium salt of dodecyl hydrogen sulfate.	1.98	1	organic sodium salt	detergent; protein denaturant
dinoprostone prostaglandin E2 : Prostaglandin F2alpha in which the hydroxy group at position 9 has been oxidised to the corresponding ketone. Prostaglandin E2 is the most common and most biologically potent of mammalian prostaglandins.	1.98	1	prostaglandins E	human metabolite; mouse metabolite; oxytocic
alprostadil [no description available]	4.93	4	prostaglandins E	anticoagulant; human metabolite; platelet aggregation inhibitor; vasodilator agent
iloprost Iloprost: An eicosanoid, derived from the cyclooxygenase pathway of arachidonic acid metabolism. It is a stable and synthetic analog of EPOPROSTENOL, but with a longer half-life than the parent compound. Its actions are similar to prostacyclin. Iloprost produces vasodilation and inhibits platelet aggregation.. iloprost : A carbobicyclic compound that is prostaglandin I2 in which the endocyclic oxygen is replaced by a methylene group and in which the (1E,3S)-3-hydroxyoct-1-en-1-yl side chain is replaced by a (3R)-3-hydroxy-4-methyloct-1-en-6-yn-1-yl group. A synthetic analogue of prostacyclin, it is used as the trometamol salt (generally by intravenous infusion) for the treatment of peripheral vascular disease and pulmonary hypertension.	4.93	4	carbobicyclic compound; monocarboxylic acid; secondary alcohol	platelet aggregation inhibitor; vasodilator agent
sq 29548 SQ 29548: SQ-26538 is the ((1S-1alpha,2beta(5Z),3beta(1E,3R*),4alpha))-isomer; thromboxane A2 antagonist; thromboxane receptor antagonist	1.98	1
9-o-methanoprostaglandin i 9-O-methanoprostaglandin I: shows weak inhibitory activity in rabbit platelet aggregation induced by ADP; RN given refers to cpd without isomeric designation	3.48	8
tei 3356 TEI 3356: a prostaglandin E receptor agonist; inhibits endothelin-induced DNA synthesis in cultured vascular smooth muscle cells; structure given in first source	1.97	1
17,20-dimethylisocarbacyclin 17,20-dimethylisocarbacyclin: improves hypothermic preservation of rat liver	1.97	1
folic acid folcysteine: used to promote fertility in chickens. vitamin B9 : Any B-vitamin that exhibits biological activity against vitamin B9 deficiency. Vitamin B9 refers to the many forms of folic acid and its derivatives, including tetrahydrofolic acid (the active form), methyltetrahydrofolate (the primary form found in blood), methenyltetrahydrofolate, folinic acid amongst others. They are present in abundance in green leafy vegetables, citrus fruits, and animal products. Lack of vitamin B9 leads to anemia, a condition in which the body cannot produce sufficient number of red blood cells. Symptoms of vitamin B9 deficiency include fatigue, muscle weakness, and pale skin.	3.35	1	folic acids; N-acyl-amino acid	human metabolite; mouse metabolite; nutrient

Condition	Relationship Strength	Studies	Trials
Cerebral Infarction, Middle Cerebral Artery [description not available]	2.93	4	0
Brain Thrombosis [description not available]	2.01	1	0
Infarction, Middle Cerebral Artery NECROSIS occurring in the MIDDLE CEREBRAL ARTERY distribution system which brings blood to the entire lateral aspects of each CEREBRAL HEMISPHERE. Clinical signs include impaired cognition; APHASIA; AGRAPHIA; weak and numbness in the face and arms, contralaterally or bilaterally depending on the infarction.	2.93	4	0
Apoplexy [description not available]	2.01	1	0
Anterior Choroidal Artery Infarction [description not available]	4.3	4	1
Blood Pressure, High [description not available]	2.4	2	0
Cerebral Infarction The formation of an area of NECROSIS in the CEREBRUM caused by an insufficiency of arterial or venous blood flow. Infarcts of the cerebrum are generally classified by hemisphere (i.e., left vs. right), lobe (e.g., frontal lobe infarction), arterial distribution (e.g., INFARCTION, ANTERIOR CEREBRAL ARTERY), and etiology (e.g., embolic infarction).	4.3	4	1
Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.	2.4	2	0
Stroke A group of pathological conditions characterized by sudden, non-convulsive loss of neurological function due to BRAIN ISCHEMIA or INTRACRANIAL HEMORRHAGES. Stroke is classified by the type of tissue NECROSIS, such as the anatomic location, vasculature involved, etiology, age of the affected individual, and hemorrhagic vs. non-hemorrhagic nature. (From Adams et al., Principles of Neurology, 6th ed, pp777-810)	2.01	1	0
Acute Brain Injuries [description not available]	2.01	1	0
Brain Injuries Acute and chronic (see also BRAIN INJURIES, CHRONIC) injuries to the brain, including the cerebral hemispheres, CEREBELLUM, and BRAIN STEM. Clinical manifestations depend on the nature of injury. Diffuse trauma to the brain is frequently associated with DIFFUSE AXONAL INJURY or COMA, POST-TRAUMATIC. Localized injuries may be associated with NEUROBEHAVIORAL MANIFESTATIONS; HEMIPARESIS, or other focal neurologic deficits.	2.01	1	0
Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.	2.01	1	0
Cerebral Ischemia [description not available]	3.24	6	0
Anterior Circulation Transient Ischemic Attack [description not available]	2.41	2	0
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	2.02	1	0
Brain Ischemia Localized reduction of blood flow to brain tissue due to arterial obstruction or systemic hypoperfusion. This frequently occurs in conjunction with brain hypoxia (HYPOXIA, BRAIN). Prolonged ischemia is associated with BRAIN INFARCTION.	3.24	6	0
Ischemic Attack, Transient Brief reversible episodes of focal, nonconvulsive ischemic dysfunction of the brain having a duration of less than 24 hours, and usually less than one hour, caused by transient thrombotic or embolic blood vessel occlusion or stenosis. Events may be classified by arterial distribution, temporal pattern, or etiology (e.g., embolic vs. thrombotic). (From Adams et al., Principles of Neurology, 6th ed, pp814-6)	2.41	2	0
Anterior Cerebral Circulation Infarction [description not available]	2.02	1	0
Brain Swelling [description not available]	2.4	2	0
Innate Inflammatory Response [description not available]	2.02	1	0
Brain Edema Increased intracellular or extracellular fluid in brain tissue. Cytotoxic brain edema (swelling due to increased intracellular fluid) is indicative of a disturbance in cell metabolism, and is commonly associated with hypoxic or ischemic injuries (see HYPOXIA, BRAIN). An increase in extracellular fluid may be caused by increased brain capillary permeability (vasogenic edema), an osmotic gradient, local blockages in interstitial fluid pathways, or by obstruction of CSF flow (e.g., obstructive HYDROCEPHALUS). (From Childs Nerv Syst 1992 Sep; 8(6):301-6)	2.4	2	0
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	2.02	1	0
Brain Infarction Tissue NECROSIS in any area of the brain, including the CEREBRAL HEMISPHERES, the CEREBELLUM, and the BRAIN STEM. Brain infarction is the result of a cascade of events initiated by inadequate blood flow through the brain that is followed by HYPOXIA and HYPOGLYCEMIA in brain tissue. Damage may be temporary, permanent, selective or pan-necrosis.	2.02	1	0
Gangrene Death and putrefaction of tissue usually due to a loss of blood supply.	1.98	1	0
Diseases, Peripheral Vascular [description not available]	3.78	2	1
Peripheral Vascular Diseases Pathological processes involving any one of the BLOOD VESSELS in the vasculature outside the HEART.	3.78	2	1
Muscle Relaxation That phase of a muscle twitch during which a muscle returns to a resting position.	2.39	2	0
Ache [description not available]	4.74	2	1
Pain An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.	4.74	2	1
Ulcer A lesion on the surface of the skin or a mucous surface, produced by the sloughing of inflammatory necrotic tissue.	6.08	4	1
Brain Vascular Disorders [description not available]	2.9	4	0
Age-Related Memory Disorders [description not available]	1.98	1	0
Brain Embolism and Thrombosis [description not available]	1.98	1	0
Cerebrovascular Disorders A spectrum of pathological conditions of impaired blood flow in the brain. They can involve vessels (ARTERIES or VEINS) in the CEREBRUM, the CEREBELLUM, and the BRAIN STEM. Major categories include INTRACRANIAL ARTERIOVENOUS MALFORMATIONS; BRAIN ISCHEMIA; CEREBRAL HEMORRHAGE; and others.	2.9	4	0
Memory Disorders Disturbances in registering an impression, in the retention of an acquired impression, or in the recall of an impression. Memory impairments are associated with DEMENTIA; CRANIOCEREBRAL TRAUMA; ENCEPHALITIS; ALCOHOLISM (see also ALCOHOL AMNESTIC DISORDER); SCHIZOPHRENIA; and other conditions.	1.98	1	0
Pulmonary Hypertension [description not available]	1.99	1	0
Hypertension, Pulmonary Increased VASCULAR RESISTANCE in the PULMONARY CIRCULATION, usually secondary to HEART DISEASES or LUNG DISEASES.	1.99	1	0
Diathesis [description not available]	1.97	1	0
Buerger Disease [description not available]	4.55	3	0

clinprost

Description

Cross-References

Synonyms (35)

Research

Studies (31)

Market Indicators

Research Demand Index: 12.08

Study Types